Scott R Evans

List of Publications by Year
in descending order

79 papers	3,566 citations	236925 25 h-index	138484 58 g-index
80 all docs	80 docs citations	80 times ranked	4597 citing authors

#	Article	IF	Citations
1	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 2018, 66, 163-171.	5.8	485
2	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 35-43.	27.0	424
3	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal of Medicine, 2020, 383, 207-217.	27.0	333
4	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clinical Infectious Diseases, 2015, 61, 800-806.	5.8	206
5	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 301-310.	10.2	174
6	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	2.2	171
7	MEASURING AND TESTING FOR SPATIAL SYNCHRONY. Ecology, 2001, 82, 1668-1679.	3.2	161
8	Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae:</i> Laboratory Detection and Impact on Mortality. Clinical Infectious Diseases, 2017, 64, ciw805.	5.8	150
9	Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network. Antimicrobial Agents and Chemotherapy, 2014, 58, 4035-4041.	3.2	132
10	The Emperorâ€™s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious Diseases, 2020, 70, 1536-1545.	5.8	106
11	Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation. Statistics in Biopharmaceutical Research, 2016, 8, 386-393.	0.8	93
12	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 2020, 51, 3504-3513.	2.0	67
13	Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. JAMA Pediatrics, 2022, 176, 253.	6.2	66
14	Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposiâ€™s Sarcoma: An AIDS Clinical Trials Group Clinical Study. Journal of Clinical Oncology, 2002, 20, 3236-3241.	1.6	64
15	Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology, 2018, 91, 403-413.	1.1	63
16	When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial. PLOS Clinical Trials, 2007, 2, e18.	3.5	62
17	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>. Journal of Antimicrobial Chemotherapy, 2015, 70, 1203-1211.	3.0	47
18	A comparison of goodness of fit tests for the logistic GEE model. Statistics in Medicine, 2005, 24, 1245-1261.	1.6	43

#	Article	IF	Citations
19	Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clinical Infectious Diseases, 2019, 68, 1691-1698.	5.8	42
20	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clinical Infectious Diseases, 2019, 68, 1823-1830.	5.8	37
21	A Randomized Trial Evaluating Prosaptide™ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS ONE, 2007, 2, e551.	2.5	36
22	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. HIV Clinical Trials, 2007, 8, 437-446.	2.0	30
23	Resist the Temptation of Response-Adaptive Randomization. Clinical Infectious Diseases, 2020, 71, 3002-3004.	5.8	30
24	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic	0.6	28
25	The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. International Journal of Stroke, 2019, 14, 745-751.	5.9	28
26	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. Statistics in Biopharmaceutical Research, 2015, 7, 36-54.	0.8	27
27	Hospital Readmissions in Patients With Carbapenem-Resistant *Klebsiella pneumoniae*. Infection Control and Hospital Epidemiology, 2016, 37, 281-288.	1.8	24
28	Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087. HIV Clinical Trials, 2007, 8, 45-52.	2.0	23
29	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2017, 4, ofx157.	0.9	22
30	Data Monitoring in Clinical Trials Using Prediction. Drug Information Journal, 2007, 41, 733-742.	0.5	21
31	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. PLoS ONE, 2015, 10, e0131001.	2.5	21
32	Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant *Klebsiella pneumoniae*. Infection Control and Hospital Epidemiology, 2015, 36, 942-948.	1.8	20
33	Pragmatic trials of pain therapies: a systematic review of methods. Pain, 2022, 163, 21-46.	4.2	20
34	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke, 2017, 48, 2480-2487.	2.0	19
35	Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials, 2022, 23, 407.	1.6	19
36	Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. Annals of Internal Medicine, 2020, 172, 119.	3.9	18

#	Article	IF	Citations
37	Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria. International Journal of STD and AIDS, 2016, 27, 938-949.	1.1	17
38	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. HIV Clinical Trials, 2008, 9, 434-439.	2.0	15
39	Analysis of ordered composite endpoints. Statistics in Medicine, 2020, 39, 602-616.	1.6	13
40	Sizing clinical trials when comparing bivariate time–to–event outcomes. Statistics in Medicine, 2017, 36, 1363-1382.	1.6	12
41	Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clinical Infectious Diseases, 2019, 68, 1739-1746.	5.8	12
42	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clinical Trials, 2020, 17, 617-626.	1.6	12
43	Goodness of Fit Tests for Logistic GEE Models: Simulation Results. Communications in Statistics Part B: Simulation and Computation, 2004, 33, 247-258.	1.2	11
44	Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts. Statistics in Biopharmaceutical Research, 2015, 7, 81-94.	0.8	10
45	Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards. , 2022, 1, .		10
46	Difficulties in Demonstrating Superiority of an Antibiotic for Multidrug-Resistant Bacteria in Nonrandomized Studies. Clinical Infectious Diseases, 2014, 59, 1142-1147.	5.8	9
47	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke, 2021, 52, 3482-3489.	2.0	9
48	Measuring and Testing for Spatial Synchrony. Ecology, 2001, 82, 1668.	3.2	9
49	A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. Open Forum Infectious Diseases, 2022, 9, .	0.9	9
50	Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2016, 4, 9-13.	1.3	8
51	Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S18-S23.	5.8	8
52	Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. Therapeutic Innovation and Regulatory Science, 2021, 55, 545-552.	1.6	8
53	Goodness of Fit Tests in Mixed Effects Logistic Models Characterized by Clustering. Communications in Statistics - Theory and Methods, 2004, 33, 1139-1155.	1.0	7
54	Group-sequential three-arm noninferiority clinical trial designs. Journal of Biopharmaceutical Statistics, 2017, 27, 1-24.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases, 2021, 73, 730-739.	5.8	7
56	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology, 2022, 99, .	1.1	7
57	Food and Drug Administration–mandated Trials of Long-Acting Î²-Agonist Safety in Asthma. Bang for the Buck?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 987-990.	5.6	6
58	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. International Journal of Stroke, 2019, 14, 908-914.	5.9	6
59	Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. Journal of Infectious Diseases, 2022, 226, 1109-1119.	4.0	6
60	Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials. Clinical Infectious Diseases, 2020, 70, 698-703.	5.8	5
61	Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product. Statistics in Biopharmaceutical Research, 2016, 8, 417-425.	0.8	4
62	Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. Open Forum Infectious Diseases, 2017, 4, ofx216.	0.9	4
63	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. Lifetime Data Analysis, 2020, 26, 266-291.	0.9	4
64	Radical Thinking: Scientific Rigor and Pragmatism. Statistics in Biopharmaceutical Research, 0, , 1-13.	0.8	4
65	Traumatic Cardiac Injury: Ventricular Perforation Caught on CT. Case Reports in Radiology, 2016, 2016, 1-3.	0.3	3
66	Our Most Important Discovery: The Question. Statistics in Biopharmaceutical Research, 0, , 1-14.	0.8	3
67	1757. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused by Escherichia coli and Klebsiella pneumoniae. Open Forum Infectious Diseases, 2018, 5, S60-S60.	0.9	2
68	Reply to Villar et al. Clinical Infectious Diseases, 2020, 73, e842-e843.	5.8	2
69	Using a Composite Maternal–Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clinical Infectious Diseases, 2020, 73, e587-e593.	5.8	2
70	Similar changes in neuropsychological functioning in english and spanish speaking <scp>HIV</scp> patients. Brain and Behavior, 2018, 8, e01083.	2.2	1
71	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. Clinical Infectious Diseases, 2020, 71, 433-439.	5.8	1
72	Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations. Statistics in Biopharmaceutical Research, 2021, 13, 181-191.	0.8	1

#	Article	IF	Citations
73	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
74	BAC DOOR: A Clinician Ranking Exercise for Better Staphylococcus aureus Bacteremia Trial Design. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
75	1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases, 2018, 5, S356-S357.	0.9	0
76	1052. Do Healthcare Providers De-Escalate Î²-Lactam (BL) Antibiotic Therapy Based on Results of Antibiotic Susceptibility Testing (AST)? Analysis of Bloodstream Infections (BSI) Caused by Escherichia coli and Klebsiella pneumoniae From the Veterans Health Administration (VHA). Open Forum Infectious Diseases, 2018, 5, S314-S315.	0.9	0
77	1041. How Do Healthcare Providers Approach Empiric Î²-Lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of Escherichia coli and Klebsiella pneumoniae BSI From the Veterans Health Administration (VHA). Open Forum Infectious Diseases, 2018, 5, S311-S311.	0.9	0
78	Reply to Humphrey and Spafford. Clinical Infectious Diseases, 2019, 69, 1831-1832.	5.8	0
79	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemporary Clinical Trials, 2021, 101, 106244.	1.8	0